Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p40-EBI3
- Development stage
- Preclinical
- Lead developer
- The Catholic University of Korea
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
p40-EBI3 is a novel heterodimeric cytokine composed of the interleukin-12 subunit p40 (IL-12p40) and Epstein-Barr virus-induced gene 3 (EBI3). Developed by researchers at The Catholic University of Korea, it acts as an immunoregulatory agent that promotes immune tolerance and suppresses inflammatory pathways. Mechanistically, p40-EBI3 suppresses STAT3 phosphorylation while promoting STAT5 activation, which downregulates the transcriptional repressor DREAM and restores the expression of the anti-inflammatory regulator A20. This reciprocal signaling shift leads to the expansion of regulatory T (Treg) cells and the suppression of pathogenic T helper 17 (Th17) cells, as well as the inhibition of osteoclastogenesis and necroptotic signaling. It is being investigated in preclinical models for the treatment of autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and systemic sclerosis.
- Other names
- p40-EBI3 complexp-40-EBI3 complexp 40-EBI3 complexp40-EBI3-Fcp-40-EBI3-Fcp 40-EBI3-Fcp40-EBI3 immunoprotein complexp-40-EBI3 immunoprotein complexp 40-EBI3 immunoprotein complex
Beyond the preview
Go deeper on p40-EBI3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p40-EBI3.